Source: Nasdaq

Karyopharm Therapeutics: Karyopharm Therapeutics Expects Q4 Revenues Of $30 Mln

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI), Monday announced preliminary fourth-quarter and full-year 2024 total revenue and U.S. XPOVIO net product revenue estimates.

Read full article »
Karyopharm Therapeutics's Competitors | Karyopharm Therapeutics's News | Karyopharm Therapeutics's Financials
Stay up-to-date with the latest news on Karyopharm Therapeutics
Annual Revenue
$100-500M
Employees
250-500
Richard Paulson's photo - President & CEO of Karyopharm Therapeutics

President & CEO

Richard Paulson

CEO Approval Rating

73/100

Read more
Stay up-to-date with the latest news on Karyopharm Therapeutics